PFE vs XOM: Which Is the Better Buy?

Side-by-side comparison of Pfizer Inc. and Exxon Mobil Corporation — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-06-20.
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
VS
Exxon Mobil Corporation · Energy
$137.81
-45.0% upside to fair value
Grade C
QuantHub Verdict
PFE has more upside to fair value (+2.8%). PFE trades at a lower forward P/E (19.2x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric PFE XOM
Current Price $25.22 $137.81
Fair Value Estimate $25.92 $75.80
Upside to Fair Value +2.8% -45.0%
Market Cap $143.7B $571.2B
Forward P/E 19.2x 22.8x
EV / EBITDA 12.3x 10.1x
Price / Sales 2.3x 1.8x
Price / FCF 15.2x 30.4x
Revenue Growth YoY +5.4% +2.6%
Gross Margin 69.3% 25.5%
Operating Margin 23.4% 9.0%
Return on Equity 8.4% 9.8%
Dividend Yield 0% 0%
FCF Yield 6.6% 3.29%
Analyst Consensus Hold Buy
Investment Thesis
PFE — Pfizer Inc.
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
XOM — Exxon Mobil Corporation
Exxon Mobil Corporation is a leading integrated oil and gas company with a durable competitive moat based on its scale, integration, advantaged long-life resources, proprietary technology, and irreplaceable infrastructure. The company is led by a long-tenured management team with a strong capital allocation track record focused on dividends and buybacks. Despite these strengths, Exxon is currentl…
Accumulation Zones
Metric PFE XOM
Zone Low $19.44 $56.85
Zone High $22.03 $64.43
In Buy Zone? No No
← PFE Research    XOM Research →    All Research